Is adjuvant trastuzumab cost-effective for HER2-positive T1bN0 breast cancer?

In light of the clinical uncertainty and the high acquisition costs of trastuzumab, a group of researchers led by Mr C. Skedgel of the Atlantic Clinical Cancer Research Unit, Centre for Clinical Research, Halifax examined the ‘value for money’ associated with adjuvant trastuzumab in women with T1bN0 breast cancer in terms of the likelihood of such a strategy meeting a $100 000 per quality-adjusted life year (QALY) gained cost-effectiveness threshold over a plausible range of baseline recurrence risks. Read more here.